参考文献/References:
[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68:394-424.
[2]Moris D,Palta M,Kim C,et al.Advances in the treatment of intrahepatic cholangiocarcinoma:an overview of the current and future therapeutic landscape for clinicians[J].CA Cancer J Clin,2023,73:198-222.
[3]Buettner S,van Vugt JL,IJzermans JN,et al.Intrahepatic cholangiocarcinoma:current perspectives[J].Onco Targets Ther,2017,10:1131-1142.
[4]Woods E,Le D,Jakka BK,et al.Changing landscape of systemic therapy in biliary tract cancer[J].Cancers(Basel),2022,14:2137.
[5]National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology:Biliary tract cancers(2023)[EB/OL].nccn.medlive.cn,2024-08-29.
[6]Oh DY,He AR,Bouattour M,et al.Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer(TOPAZ-1):updated overall survival from a randomised phase 3 study[J].Lancet Gastroenterol Hepatol,2024,9:694-704.
[7]Kelley RK,Ueno M,Yoo C,et al.Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer(KEYNOTE-966):a randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet,2023,401:1853-1865.
[8]Edeline J,Bridgewater J,Campillo-Gimenez B,et al.Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma:data from clinical trials[J].Hepatology,2024,79:96-106.
[9]沈颖甜,朱海东,陈 荔,等.肝内胆管细胞癌诊疗研究进展[J].介入放射学杂志,2018,27:285-289.
[10]Owen M,Makary MS,Beal EW.Locoregional therapy for intrahepatic cholangiocarcinoma[J].Cancers(Basel),2023,15:2384.
[11]Ahmed M,Solbiati L,Brace CL,et al.Image-guided tumor ablation:standardization of terminology and reporting criteria:10-year update[J].J Vasc Interv Radiol,2014,25:1691-1705.
[12]徐中琪,甘 伟,刘 晟,等.经皮热消融治疗术后复发型肝内胆管细胞癌疗效分析[J].介入放射学杂志,2016,25:973-976.
[13]Edeline J,Lamarca A,McNamara MG,et al.Locoregional therapies in patients with intrahepatic cholangiocarcinoma:a systematic review and pooled analysis[J].Cancer Treat Rev,2021,99:102258.
[14]Iezzi R,Gangi A,Posa A,et al.Emerging indications for interventional oncology:expert discussion on new locoregional treatments[J].Cancers(Basel),2023,15:308.
[15]Woodhead G,Lee S,Struycken L,et al.Interventional radiology locoregional therapies for intrahepatic cholangiocarcinoma[J].Life(Basel),2024,14:217.
[16]Kim GH,Kim PH,Kim JH,et al.Thermal ablation in the treatment of intrahepatic cholangiocarcinoma:a systematic review and meta-analysis[J].Eur Radiol,2022,32:1205-1215.
[17]Brandi G,Rizzo A,Dall'Olio FG,et al.Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma:a retrospective single-center experience[J].Int J Hyperthermia,2020,37:479-485.
[18]孙 巍,丁晓燕,陈京龙,等.射频消融联合系统化疗治疗不可切除或术后复发肝内胆管癌的效果和安全性[J].临床肝胆病杂志,2018,34:1717-1722.
[19]魏 春,刘 宇,李 波,等.微波消融联合全身化疗治疗复发性肝内胆管癌的有效性与安全性分析[J].临床肝胆病杂志,2023,39:1609-1616.
[20]Yan X,Zhuang LP,Ning ZY,et al.Addition of thermal ablation to systemic chemotherapy for the treatment of unresectable intrahepatic cholangiocarcinoma:a propensity score matching analysis[J].Expert Rev Gastroenterol Hepatol,2022,16:81-88.
[21]Yin L,Li X,Zhu L,et al.Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy[J].Front Immunol,2022,13:965120.
[22]Han K,Ko HK,Kim KW,et al.Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma:systematic review and meta-analysis[J].J Vasc Interv Radiol,2015,26:943-948.
[23]科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究”专家组.肝内胆管癌外科治疗中国专家共识(2020版)[J].中华消化外科杂志,2021,20:1-15.
[24]中国医师协会介入医师分会临床诊疗指南专委会.中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2023年版)[J].中华医学杂志,2023,103:2674-2694.
[25]Gaba RC,Lewandowski RJ,Hickey R,et al.Transcatheter therapy for hepatic malignancy:standardization of terminology and reporting criteria[J].J Vasc Interv Radiol,2016,27:457-473.
[26]Breedis C,Young G.The blood supply of neoplasms in the liver[J].Am J Pathol,1954,30:969-977.
[27]Luo J,Zheng J,Shi C,et al.Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients:a preliminary result from CTILC study[J].Medicine(Baltimore),2020,99:e19276.
[28]Sun T,Zhang W,Chen L,et al.A comparative study of efficacy and safety of transarterial chemoembolization with CalliSpheres and conventional transarterial chemoembolization in treating unresectable intrahepatic cholangiocarcinoma patients[J].J Cancer,2022,13:1282-1288.
[29]He M,Jiang N,Yin X,et al.Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma:a systematic review and pooled analysis[J].J Cancer Res Clin Oncol,2023,149:531-540.
[30]Martin RCG,Simo KA,Hansen P,et al.Drug-eluting bead,irinotecan therapy of unresectable intrahepatic cholangiocarcinoma(DELTIC)with concomitant systemic gemcitabine and cisplatin[J].Ann Surg Oncol,2022,29:5462-5473.
[31]Jiang N,Zhang Z,Yin X,et al.Systemic chemotherapy plus transarterial chemoembolization versus systemic chemotherapy alone for unresectable intrahepatic cholangiocarcinoma:a multicenter retrospective cohort study[J].Radiol Med,2024,129:631-642.
[32]Gairing SJ,Thol F,Müller L,et al.The Addition of transarterial chemoembolization to palliative chemotherapy extends survival in intrahepatic cholangiocarcinoma[J].J Clin Med,2021,10:2732.
[33]Luo S,Xiang Z,Li M,et al.Clinical effectiveness of drug-eluting microsphere transcatheter arterial chemoembolization combined with first-line chemotherapy as the initial treatment for patients with unresectable intrahepatic cholangiocarcinoma[J].J Vasc Interv Radiol,2024,35:1616-1625.
[34]Hu Y,Hao M,Chen Q,et al.Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization(TACE),apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma[J].Am J Transl Res,2020,12:6584-6598.
[35]Yuan P,Song J,Wang F,et al.Combination of TACE and Lenvatinib as a promising option for downstaging to surgery of initially unresectable intrahepatic cholangiocarcinoma[J].Invest New Drugs,2022,40:1125-1132.
[36]Tan S,Day D,Nicholls SJ,et al.Immune checkpoint inhibitor therapy in oncology:current uses and future directions:JACC:Cardio oncology state-of-the-art review[J].JACC CardioOncol,2022,4:579-597.
[37]Wallin J,Bendell JC,Funke R,et al.Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma[J].Nat Commun,2016,7:12624.
[38]Jiang J,Diaz DA,Nuguru SP,et al.Stereotactic body radiation therapy(SBRT)plus immune checkpoint inhibitors(ICI)in hepatocellular carcinoma and cholangiocarcinoma[J].Cancers(Basel),2022,15:50.
[39]Yang XG,Sun YY,Li DS,et al.Efficacy and safety of drug-eluting beads transarterial chemoembolization combining immune checkpoint inhibitors in unresectable intrahepatic cholangiocarcinoma:a propensity score matching analysis[J].Front Immunol,2022,13:940009.
[40]Zhang H,Han C,Zheng X,et al.Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma:a case report and literature review[J].J Cancer Res Ther,2023,19:1055-1060.
[41]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma[J].J Hepatol,2018,69:182-236.
[42]Somma F,Stoia V,Serra N,et al.Yttrium-90 trans-arterial radioembolization in advanced-stage HCC:The impact of portal vein thrombosis on survival[J].PLoS One,2019,14:e0216935.
[43]Schartz DA,Porter M,Schartz E,et al.Transarterial yttrium-90 radioembolization for unresectable intrahepatic cholangiocarcinoma:a systematic review and meta-analysis[J].J Vasc Interv Radiol,2022,33:679-686.
[44]王草叶,郑 扬,胡红杰,等.钇-90微球在治疗不可切除且其它治疗方法失败的肝内胆管细胞癌中的应用——钇-90微球放射栓塞系列回顾(八)[J].介入放射学杂志,2018,27:1107-1114.
[45]Gupta AN,Gordon AC,Gabr A,et al.Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma:long-term follow-up for a 136-patient cohort[J].Cardiovasc Intervent Radiol,2022,45:1117-1128.
[46]Cocozza M,Dajti E,Braccischi L,et al.Survival after transarterial radioembolization in patients with unresectable intrahepatic cholangiocarcinoma:an updated meta-analysis and meta-regression[J].Cardiovasc Intervent Radiol,2024,47:1313-1324.
[47]Kis B,Shridhar R,Mhaskar R,et al.Radioembolization with yttrium-90 glass microspheres as a first-line treatment for unresectable intrahepatic cholangiocarcinoma:a prospective feasibility study[J].J Vasc Interv Radiol,2023,34:1547-1555.
[48]Morse B,McGettigan M,Kis B.Percutaneous liver-directed therapies of intrahepatic cholangiocarcinoma[J].Abdom Radiol(NY),2024,49:4257-4263.
[49]Cucchetti A,Cappelli A,Mosconi C,et al.Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma:a meta-regression study[J].Liver Int,2017,37:1056-1064.
[50]Edeline J,Touchefeu Y,Guiu B,et al.Radioembolization plus chemotherapy for first-line treatment of locally advanced intrahepatic cholangiocarcinoma:A phase 2 clinical trial[J].JAMA Oncol,2020,6:51-59.
[51]National Library of Medicine.(2015).Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma.ClinicalTrials.gov identifier:NCT02512692[EB/Ol].https:∥clinicaltrials.gov/ct2/show/NCT02512692,2024-10-15.
[52]Kumari D,Ahmed O,Jilani S,et al.A review of professional liability in IR:Sweeping the Mines[J].J Vasc Interv Radiol,2023,34:157-163.
[53]梁 斌,郑传胜.肝动脉灌注化疗治疗肝细胞癌临床研究进展[J].中华放射学杂志,2024,58:977-982.
[54]Franssen S,Holster J,Jolissaint J,et al.Gemcitabine with cisplatin versus hepatic arterial infusion pump chemotherapy for liver-confined unresectable intrahepatic cholangiocarcinoma[J].Ann Surg Oncol,2024,31:115-124.
[55]Rossi AJ,Khan TM,Luna AJ,et al.Hepatic artery infusion pump(HAIP)therapy versus chemotherapy in the first-line setting for patients with unresectable intrahepatic cholangiocarcinoma[J].Ann Surg Oncol,2022,29:35-36.
[56]Ishii M,Itano O,Morinaga J,et al.Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine,cisplatin,and 5-fluorouracil for intrahepatic cholangiocarcinoma[J].PLoS One,2022,17:e0266707.
[57]Jolissaint JS,Soares KC,Seier KP,et al.Intrahepatic cholangiocarcinoma with lymph node metastasis:Treatment-related outcomes and the role of tumor genomics in patient selection[J].Clin Cancer Res,2021,27:4101-4108.
[58]Franssen S,Soares KC,Jolissaint JS,et al.Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma[J].JAMA Surg,2022,157:590-596.
[59]Konstantinidis IT,Groot Koerkamp B,Do RK,et al.Unresectable intrahepatic cholangiocarcinoma:Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J].Cancer,2016,122:758-765.
[60]Cercek A,Boerner T,Tan BR,et al.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma:a phase 2 clinical trial[J].JAMA Oncol,2020,6:60-67.
[61]Livshits Z,Rao RB,Smith SW.An approach to chemotherapy-associated toxicity[J].Emerg Med Clin North Am,2014,32:167-203.
[62]Pietge H,Sanchez-Velazquez P,Akhoundova D,et al.Combination of HAI-FUDR and systemic gemcitabine and cisplatin in unresectable cholangiocarcinoma:a dose finding single center study[J].Oncology,2021,99:300-309.
[63]Higaki T,Aramaki O,Moriguchi M,et al.Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma[J].Biosci Trends,2018,12:73-78.
[64]陈 朝,段洁营,丁文金.肝动脉灌注联合吉西他滨化疗治疗进展期肝内胆管细胞癌的价值体会[J].临床研究,2019,27:118-120.
[65]周胜前,兰 淑.肝动脉灌注联合吉西他滨对进展期肝内胆管细胞癌的疗效[J].中国现代普通外科进展,2020,23:573-575.
[66]Zhang N,Yu BR,Wang YX,et al.Clinical outcomes of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and anti-PD-1 immunotherapy for unresectable intrahepatic cholangiocarcinoma[J].J Dig Dis,2022,23:535-545.
[67]Lin YS,Li S,Yang X,et al.First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma[J].J Cancer Res Clin Oncol,2024,150:309.
[68]Wang Y,Wei Z,Zhang Z,et al.Hepatic arterial infusion chemotherapy with or without lenvatinib for unresectable cholangiocarcinoma:a single-center retrospective study[J].Hepat Oncol,2023,10:HEP49.
[69]Zheng Z,Wang J,Wu T,et al.Hepatic arterial infusion chemotherapy plus targeted therapy and immunotherapy versus systemic chemotherapy for advanced intrahepatic cholangiocarcinoma:a retrospective cohort study[J].Int J Surg,2024.
[70]Zhao R,Zhou J,Miao Z,et al.Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma[J].Front Immunol,2024,15:1397827.
[71]Huang Y,Du Z,Kan A,et al.Clinical and biomarker analyses of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitor for patients with advanced intrahepatic cholangiocarcinoma[J].Front Immunol,2024,15:1260191.
[72]Song S,Liu Y,Ren Y,et al.Hepatic arterial infusion chemotherapy combined with toripalimab and surufatinib for the treatment of advanced intrahepatic cholangiocarcinoma[J].Diagn Interv Radiol,2024.
[73]Zhou BJ,Wang WS,Yin Y,et al.Preliminary clinical use of hepatic arterial infusion chemotherapy combined with lenvatinib and tislelizumab in the treatment of unresectable intrahepatic cholangiocarcinoma[J].Zhonghua Nei Ke Za Zhi,2024,63:769-775.
[74]Ni JY,Sun HL,Guo GF,et al.Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma[J].Int Immunopharmacol,2024,140:112872.
[75]Zhao R,Zhou J,Xiong X,et al.Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma[J].Am J Cancer Res,2024,14:4922-4934.
[76]Lin YS,Li S,Yang X,et al.First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma[J].J Cancer Res Clin Oncol,2024,150:309.
[77]Yoo C,Hyung J,Chan SL.Recent advances in systemic therapy for advanced intrahepatic cholangiocarcinoma[J].Liver Cancer,2024,13:119-135.
[78]Li KS,Liu Y,Zhang TZ,et al.Protocol of REACH-01:a single-arm,open label,prospective study of HAIC sequential TAE combined with tislelizumab and surufatinib in unresectable intrahepatic cholangiocarcinoma[J].Front Pharmacol,2024,15:1435639.
[79]Erratum[J].J Interv Med,2023,6:143.
[80]Luo J,Zheng J,Yao H,et al.Radioactive(125)I seed inhibits cell migration and invasion and promotes apoptosis by inactivating the VEGFR2 signaling pathway in cholangiocarcinoma[J].Dose Response,2023,21:15593258231187348.
[81]Luo J,Yao Z,Liang W,et al.Mechanistic insights into(125)I seed implantation therapy for cholangiocarcinoma:focus on ROS-Mediated apoptosis and the role of GPX2[J].J Cancer Res Clin Oncol,2024,150:324.
[82]Kang F,Wu J,Hong L,et al.Iodine-125 seed inhibits proliferation and promotes apoptosis of cholangiocarcinoma cells by inducing the ROS/p53 axis[J].Funct Integr Genomics,2024,24:114.
[83]李 航.125I粒子治疗不可切除的或切除后局部区域复发的肝内胆管细胞癌[D],2022.
[84]陈 涛,朱晓黎,王万胜,等.125I粒子植入内照射治疗肝内胆管细胞癌疗效及安全性的初步分析[J].医学影像学杂志,2017,27:1276-1280.
[85]Xu Z,Xu M,Li M,et al.Effects of 125I seed stent implantation combined with arterial infusion chemoembolization on tumor markers,p53 expression,and prognosis in patients with cholangiocarcinoma[J].Bioengineered,2022,13:2943-2950.
[86]张贵军,李 宏,马霁波,等.125I放射性粒子植入术联合射频消融在中晚期肝内胆管细胞癌治疗中的临床价值[J].中华全科医学,2019,17:577-579.
[87]Luo J,Shao GL,Yao HX,et al.The efficacy and safety of biliary stenting alone versus stenting combined with iodine-125 seed strand implantation for the treatment of cholangiocarcinoma with malignant obstructive jaundice:a prospective,nonrandomized,controlled clinical study[J].Ann Palliat Med,2022,11:2422-2431.
[88]柴 杰,鲁 东,吕维富,等.经皮肝穿刺胆道125I粒子支架植入治疗恶性胆道梗阻疗效及安全性分析[J].介入放射学杂志,2022,31:702-706.
[89]Wang HW,Li XJ,Li SJ,et al.Biliary stent combined with iodine-125 seed strand implantation in malignant obstructive jaundice[J].World J Clin Cases,2021,9:801-811.
[90]俞 雪,刘 艳,沈天皓,等.经皮肝穿刺胆道引流术联合125I粒子条治疗肝内胆管细胞癌合并恶性梗阻性黄疸的临床疗效观察[J].现代消化及介入诊疗,2023,28:497-501.
[91]郁泽宇,余 辉,刁崚峰,等.胆道支架联合125I粒子条植入治疗恶性梗阻性黄疸预后因素分析[J].介入放射学杂志,2024,33:758-762.
(收稿日期:2024-11-05)
(本文编辑:谷 珂)